Stifel analyst Rick Wise maintains $Abbott Laboratories (ABT.US)$ with a buy rating, and adjusts the target price from $115 to $130.
According to TipRanks data, the analyst has a success rate of 57.8% and a total average return of 3.9% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Abbott Laboratories (ABT.US)$'s main analysts recently are as follows:
Following Q3 results, modest adjustments have been made to the forecasting model, indicating that Abbott is well-positioned to handle any competitive pressures from pulsed field ablation. Additionally, the prospects of leadless pacing may contribute to an acceleration of cardiac rhythm management growth to exceed 3%. Despite an excellent setup and strong operational execution, it is suggested that Street expectations are currently reflected in the valuation, which appears fair when compared with industry peers.
Abbott's Q3 sales exceeded expectations, bolstered by the strong performance of MedTech and the demand for COVID tests. The company also reaffirmed its organic growth guidance for FY24 and slightly raised the midpoint of its EPS forecast. Despite the positive results, the valuation and ongoing litigation present concerns, though the company's performance provides a positive outlook.
Abbott's management has indicated optimism about the company's capability to maintain high-single-digit revenue growth and double-digit earnings growth moving forward. The CEO's assertion that high-single digit revenue growth and 10% earnings per share growth is a realistic baseline reflects confidence in the company's trajectory. Abbott appears to be favorably positioned with several new offerings in the rapidly expanding Diabetes Care and Structural Heart sectors, suggesting the company's medical device portfolio is primed for robust growth in the MedTech industry.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析师Rick Wise维持$雅培 (ABT.US)$买入评级，并将目标价从115美元上调至130美元。
根据TipRanks数据显示，该分析师近一年总胜率为57.8%，总平均回报率为3.9%。
此外，综合报道，$雅培 (ABT.US)$近期主要分析师观点如下：
在Q3的业绩结果后，对预测模型进行了适度调整，表明雅培公司有能力处理来自脉冲场消融的任何竞争压力。此外，无导联起搏的前景可能有助于加速心脏节律管理增长超过3%。尽管布局优良，运营执行强劲，但街头预期目前已反映在估值中，与行业同行相比，估值看起来是公平的。
雅培公司的Q3销售超出预期，得益于医疗技术表现强劲和COVID检测需求的增加。该公司还重申了FY24的有机增长指引，并略微提高了EPS预测的中间点。尽管结果积极，但估值和持续性诉讼仍存在担忧，尽管公司的表现提供了积极的展望。
雅培公司管理层表示乐观，认为公司有能力保持高个位数的营业收入增长和两位数的收益增长。首席执行官断言，高个位数的营收增长和10%的每股收益增长是一个现实的基准，反映了对公司发展路径的信恳智能。雅培公司似乎占据有利地位，其在迅速扩展的糖尿病护理和结构心脏领域推出了几款新产品，这表明公司的医疗器械组合已经做好准备在医疗技术行业蓬勃增长。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
